You are here: Industry Insights > Incyte

News List

FDA approves Incyte’s Pemazyre as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma pharmaceutical-business-review
April 22, 2020
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre™ (pemigatinib).
Incyte begins Phase III trial of ruxolitinib to treat Covid-19 pharmaceutical-technology
April 21, 2020
Incyte has started a Phase III clinical trial of ruxolitinib (Jakafi) to treat cytokine storm caused by Covid-19 coronavirus infection.
US clears first targeted treatment for cholangiocarcinoma pharmatimes
April 20, 2020
US regulators have approved Incyte's Pemazyre as the first targeted treatment for cholangiocarcinoma.
Novartis and Incyte to trial Jakavi for Covid-19 pharmaceutical-technology
April 06, 2020
Novartis, in alliance with Incyte, has announced plans to evaluate Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm pharmatimes
April 03, 2020
Novartis and Incyte are planning to launch a clinical study to test the potential of Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm.
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug pharmaceutical-technology
January 15, 2020
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
Itacitinib Study for Treatment-Naïve Acute Graft-Versus-Host Disease Does Not Meet Primary Endpoint americanpharmaceuticalreview
January 06, 2020
Incyte announced the pivotal Phase 3 GRAVITAS-301 study evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease (GVHD) did not meet the primary endpoint of improving overall response rate
Incyte and Zai Lab enter into $77.5M collaboration biospectrumasia
July 08, 2019
Incyte will retain an option to assist in the promotion of INCMGA0012 in Zai Lab’s licensed territories
BriaCell Announces Clinical Trial Collaboration Agreement with Incyte pharmafocusasia
April 03, 2019
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply agreement (the “Agreement”) with Incyte ...
GlaxoSmithKline, Incyte, Novo Nordisk SHARE pharmaceutical-technology
December 24, 2018
GlaxoSmithKline (GSK) and Pfizer have agreed to combine their consumer healthcare businesses with combined annual sales of £9.8bn ($12.7bn) and establish a joint venture (JV).....

Previous page 1 2 3 4 5 Next page